Table 2.
Predictors of response to vaccine in BCR-ABL1-negative MPN patients.
| Variable | No. of patients | No. (%) of responders | Anti-spike (U/mL) median |
|---|---|---|---|
| All | 62 | 48 (77.4) | 743 |
| Vaccine type | |||
| Moderna | 40 | 29 (72.5) | 761 |
| Pfizer-BioNTech | 22 | 19 (86.4) | 726 |
| p-Value | 0.21 | 0.32 | |
| Gender | |||
| Men | 35 | 25 (71.4) | 726 |
| Women | 27 | 23 (85.2) | 796 |
| p-Value | 0.19 | 0.35 | |
| Age at vaccination | |||
| <70 years | 29 | 24 (82.8) | 1007 |
| ≥70 years | 33 | 24 (72.7) | 208 |
| p-Value | 0.34 | 0.03 | |
| Body mass index (kg/m2) | |||
| <25 | 35 | 27 (77.1) | 726 |
| ≥25 | 27 | 21 (77.8) | 761 |
| p-value | 0.95 | 0.90 | |
| Diagnosis | |||
| Other MPN | 36 | 33 (91.7) | 885 |
| Myelofibrosis | 26 | 15 (57.7) | 187 |
| p-Value | 0.002 | 0.0001 | |
| Neutrophils count | |||
| ≤5 × 109/L | 28 | 23 (82.1) | 278 |
| >5 × 109/L | 34 | 25 (73.5) | 885 |
| p-Value | 0.42 | 0.55 | |
| Lymphocytes count | |||
| ≤1.5 × 109/L | 33 | 27 (81.8) | 278 |
| >1.5 × 109/L | 29 | 21 (72.4) | 1688 |
| p-Value | 0.38 | 0.37 | |
| Time from MPN diagnosis to vaccination | |||
| <10 years | 33 | 25 (75.8) | 726 |
| ≥10 years | 29 | 23 (79.3) | 761 |
| p-Value | 0.74 | 0.57 | |
| Time from start of ongoing therapy to vaccination | |||
| <3 years | 25 | 18 (72.0) | 170 |
| ≥3 years | 32 | 26 (81.3) | 1574 |
| p-Value | 0.40 | 0.013 | |
| Treatment | |||
| Other | 32 | 28 (87.5) | 1958 |
| Ruxolitinib | 30 | 20 (66.7) | 148 |
| p-Value | 0.05 | <0.0001 | |
| Lines of therapy | |||
| 1 | 24 | 20 (83.3) | 782 |
| >1 | 33 | 24 (72.7) | 269 |
| p-Value | 0.34 | 0.13 |
*From chi-squared (for percentage of responders) or Mann–Whitney (for anti-Spike titer) test.
Bold values indicates statistically significant p values.